Efficacy of Intravaginal Dehydroepiandrosterone (DHEA) on Moderate to Severe Dyspareunia and Vaginal Dryness, Symptoms of Vulvovaginal Atrophy, and of the Genitourinary Syndrome of Menopause

Fernand Labrie, MD, PhD; David F. Archer, MD; William Koltun, MD; Andrée Vachon, MD; Douglas Young, MD; Louise Frenette, MD; David Portman, MD; Marlene Montesino, MD; Isabelle Côté, BSc; Julie Parent, PhD; Lyne Lavoie, MSc; Adam Beauregard, BSc, MBA; Céline Martel, PhD; Mario Vaillancourt, BSc, MBA; John Balser, PhD; Érick Moyneur, BSc, MA; the members of the VVA Prasterone Research Group


Menopause. 2016;23(3):243-256. 

In This Article


The current study describes the efficacy of DHEA for the management of VVA. Intravaginal DHEA improved vaginal pH, superficial and basal epithelial cell counts, and relieved dyspareunia, the MBS found in the majority of postmenopausal women. Moderate to severe vaginal dryness accompanied dyspareunia in 84% of women and was similarly improved by DHEA (Prasterone) treatment. Physical assessment of the vagina with a speculum demonstrated improvement in vaginal secretions, epithelial integrity, epithelium thickness, and also vaginal color in the DHEA arm, compared with placebo. Overall, DHEA acting by strictly local mechanisms in the vagina shows clinical and highly statistically significant improvement of all recognized subjective and objective elements of VVA and dyspareunia compared with placebo.